ストックスクリーナーアプリを入手
161.28
1.89%
2.99
アフターアワーズ：
161.28
前日終値:
$158.29
開ける：
$159.21
24時間の取引高:
723.32K
Relative Volume:
0.50
時価総額：
$11.17B
収益：
$2.90B
当期純損益:
$302.80M
株価収益率:
37.54
EPS:
4.2965
ネットキャッシュフロー:
$387.80M
1週間 パフォーマンス:
-1.95%
1か月 パフォーマンス:
+7.01%
6か月 パフォーマンス:
-44.20%
1年 パフォーマンス:
-45.77%
1日の値動き範囲:
$158.30
$161.82
1週間の範囲:
$153.64
$164.40
52週間の値動き範囲:
$138.79
$354.88
Insulet Corp Stock (PODD) Company Profile
Compare PODD vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
161.28 | 11.17B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | ダウングレード | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2026-01-27 | 再開されました | TD Cowen | Hold |
| 2026-01-12 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-12-16 | 開始されました | Evercore ISI | Outperform |
| 2025-11-19 | アップグレード | UBS | Neutral → Buy |
| 2025-10-21 | 再開されました | Stifel | Buy |
| 2025-09-08 | 再開されました | Oppenheimer | Outperform |
| 2025-06-16 | 開始されました | Truist | Buy |
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-05-13 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-11-06 | 開始されました | Bernstein | Outperform |
| 2024-05-30 | 開始されました | Redburn Atlantic | Buy |
| 2024-05-07 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-21 | アップグレード | Citigroup | Neutral → Buy |
| 2023-08-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-01-26 | 開始されました | Wolfe Research | Peer Perform |
| 2022-11-04 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-07-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-02-02 | アップグレード | UBS | Neutral → Buy |
| 2022-01-31 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-07-28 | 開始されました | Wells Fargo | Overweight |
| 2020-04-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | 開始されました | BofA/Merrill | Neutral |
| 2020-03-31 | ダウングレード | Berenberg | Buy → Hold |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-12-10 | 開始されました | CFRA | Sell |
| 2019-10-23 | 開始されました | Stifel | Hold |
| 2019-10-18 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | ダウングレード | BTIG Research | Buy → Neutral |
| 2019-10-04 | ダウングレード | UBS | Buy → Neutral |
| 2019-10-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-08-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-06-10 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | アップグレード | BTIG Research | Neutral → Buy |
| 2018-04-20 | 開始されました | Berenberg | Buy |
| 2018-02-22 | 繰り返されました | Barclays | Overweight |
| 2018-01-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | 開始されました | Barclays | Overweight |
すべてを表示
Insulet Corp (PODD) 最新ニュース
PODD EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - GlobeNewswire Inc.
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
PODD Shareholder Alert: Insulet Corporation Securities - GlobeNewswire
Stifel cuts Insulet stock price target on valuation, keeps buy rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Insulet stock reflects steady diabetes tech demand as investors watch U.S. growth - AD HOC NEWS
Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47% - Yahoo Finance
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 31, 2026 in Insulet Corporation LawsuitPODD - Morningstar
PODD Shareholder Alert: Insulet Corporation Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - Business Wire
Insulet focuses on diabetes technology growth. Business model supports recurring revenue - Ad-hoc-news.de
Levi & Korsinsky Reminds Insulet Corporation Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 31, 2026PODD - Morningstar
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
PODD Maintained by Citigroup -- Price Target Raised to $172 - GuruFocus
Insulet (PODD) Launches Omnipod 5 In Spain, Is The Upside Already Priced In? - simplywall.st
Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut? - Yahoo Finance
Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain - Yahoo Finance
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit - PR Newswire
Form 4 Insulet Corporation For: 7 July By Investing.com - Investing.com Nigeria
Insulet Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Insulet (PODD) director updates award to 151 deferred stock units - Stock Titan
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now? - Yahoo Finance
Why Insulet (PODD) Could Beat Earnings Estimates Again - Yahoo Finance
Insulet launches Omnipod 5 in Spain - MedTech Dive
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
PODD DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Insulet Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - Morningstar
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target - Insider Monkey
FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports - Benzinga
Class action lawsuit filed against Insulet over alleged false statements causing investor losses - Pluang
INSULET CORPORATION (PODD) INVESTOR ALERT Investors With - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm - Barchart.com
Insulet Misled Investors on Manufacturing Procedures, Suit Says - Bloomberg Law News
PODD Expands Omnipod 5 Launch to Spain, Enhancing Diabetes Care - GuruFocus
Insulet launches Omnipod 5 insulin system in Spain - Investing.com
Insulet launches Omnipod 5 insulin system in Spain By Investing.com - Investing.com South Africa
Insulet brings tubeless diabetes tech to Spain with Omnipod 5 launch - Stock Titan
VERI DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Veritone, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
PODDInsulet Corp Latest SEC Filings - Finviz
Rosen Law Firm Urges Insulet Corporation (NASDAQ: PODD) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Class action lawsuit filed against Insulet over alleged false statements on product safety. - Pluang
Bernstein SocGen cuts Insulet stock price target on valuation concerns - Investing.com
Insulet faces shareholder lawsuit over alleged false safety claims and product issues. - Pluang
Class action filed against Insulet over alleged product safety and disclosure issues, stock drops follow. - Pluang
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation - GlobeNewswire
Grabar Law Office Investigates Claims on Behalf of Shareholders of Insulet Corporation (PODD) - TMX Newsfile
FDA Alerts on Insulet (PODD) Device Safety Concerns - GuruFocus
Insulet (PODD) Faces Class I Recall of Omnipod Insulin Pump Syst - GuruFocus
Insulet Corporation: A High-Quality Growth Story Trading At A Reasonable PEG - Seeking Alpha
Class action lawsuit filed against Insulet over defective insulin delivery systems and stock drops. - Pluang
Insulet Corp (PODD) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
大文字化:
|
ボリューム (24 時間):